For Approved Qualified Domestic Institutional Investors in China

Global Life Sciences Fund

By understanding the science and business of health care, our experienced team invests in companies addressing unmet medical needs or those that seek to make the health care system more efficient.

ISIN
IE0009355771

NAV
USD 46.82
As of 2023/09/26

1-Day Change
USD -0.17 (-0.36%)
 As of 2023/09/26

Morningstar Rating

As of 2023/08/31

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (also known as equities) selected for their growth potential and with a life sciences orientation. The Fund may invest in companies of any size, in any country.

Less

ABOUT THIS FUND

  • Looks to invest in companies addressing unmet medical needs or those that seek to make the health care system more efficient
  • Aims to maintain a balanced portfolio across subsectors (biotechnology, health care services, medical devices and pharmaceuticals)
  • An experienced team of specialists that seeks to understand the science and the business of health care

PORTFOLIO MANAGEMENT

Andy Acker, CFA

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Performance

Cumulative Performance (%)
As of 2023/08/31
A2 USD
 
  Cumulative
  1MO 3MO 6MO YTD 1YR 3YR 5YR Since Inception
2000/03/31
A2 USD -1.53 2.28 6.22 1.86 12.12 14.84 38.92 388.30
Source: Morningstar, Inc., NAV-NAV, gross income reinvested where applicable. Past performance cannot guarantee future results.
FEE INFORMATION
Initial Charge 5.00%
Annual Charge 1.50%
Ongoing Charge
(As of 2023/06/30) 		2.39%
The ongoing charge is calculated using the Packaged Retail Investment Product (PRIIPs) methodology. The PRIIPs methodology differs to the UCITS ongoing charge methodology, as the PRIIPS methodology captures additional recurring charges, including but not limited to: a. Interest paid on borrowing (e.g. bank interest) b. Any fees incurred in relation to stock-lending activity (i.e. the fee paid to the lending agent) c. Any costs associated with holding closed-ended vehicles.
Please refer to the offering documents for more details on the fees and expenses.

Portfolio

Top Holdings (As of 2023/08/31)
% OF FUND
UnitedHealth Group Inc 6.09
Eli Lilly & Co 4.77
AstraZeneca PLC 3.93
Novo Nordisk A/S 3.58
Sanofi 2.94
Merck & Co Inc 2.83
Abbott Laboratories 2.63
AbbVie Inc 2.47
Sarepta Therapeutics Inc 2.44
Thermo Fisher Scientific Inc 2.43
Total 34.11
Portfolio holdings are subject to change without notice. 
Sector Allocation % OF FUND % OF FUND (As of 2023/08/31)
Regional Allocation % OF FUND % OF FUND (As of August 31, 2023)

Documents

Related Insights

Our intellectual capital is readily available and central to our Knowledge Shared approach"
Related Insights
Hiding in plain sight: The investment case for healthcare
11 Sep 2023
Timely & Topical

Hiding in plain sight: The investment case for healthcare

Why attractive valuations and new growth opportunities make healthcare worthy of another look by investors.

7 min read

JH Explorer in San Diego: The future of treating diabetes
23 Aug 2023
Timely & Topical

JH Explorer in San Diego: The future of treating diabetes

A new approach to treating diabetes could lead to weight loss and cardiovascular benefits, unlocking the potential for significant growth.

4 min read

Keeping perspective on AI’s role in biotech
15 Jun 2023
Timely & Topical

Keeping perspective on AI’s role in biotech

While technology is an important aspect of drug discovery, the value of new medicines – and the firms developing them – comes down to the quality of clinical data.

3 min read